Kali, Inc (KALY) Fair Value & Analysis
Healthcare · US · Market cap $102K
Kali, Inc
KALY · US
Fair value as of: Jul 29, 2026
From 3 valuation models · updated 12 days ago
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from $0.0001 (bear) to $0.0001 (bull), base $0.0001. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 51/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0001 – $0.0277 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Jul 29, 2026.
Analysis
Kali, Inc (KALY) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Kali, Inc generated revenue of $106M at a net margin of 19.9%. Revenue grew 75.5% year over year. It earns a return on equity of 33.0%. Fundamentals as of Jul 29, 2026
The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 0%, KALY screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: DCF Models ($0.0001) versus DCF Models ($0.0001). Highest evidence: EV/EBITDA (54).
Notify me when KALY reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 100
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Kali, Inc., doing business as Kali-Extracts, Inc., engages in the research and development of cannabis treatments for various illnesses, diseases, and chronic pain as a symptom of various diagnoses. It provides pharmaceuticals, cannabis extracts, and health and wellness products. The company was formerly known as VLOV Inc. and changed its name to Kali, Inc.
Full company description
Kali, Inc., doing business as Kali-Extracts, Inc., engages in the research and development of cannabis treatments for various illnesses, diseases, and chronic pain as a symptom of various diagnoses. It provides pharmaceuticals, cannabis extracts, and health and wellness products. The company was formerly known as VLOV Inc. and changed its name to Kali, Inc. in February 2016. Kali, Inc. is based in Dallas, Texas.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2011 – FY2016 · reported fiscal years
Kali, Inc reported revenue of $71.5K in FY2016 versus $88.8M in FY2011, a compound −75.9%/yr. Reported net income was $1.4K in FY2016, compounding −84.2%/yr from FY2011.
Watch KALY: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Kali, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Kali, Inc (KALY) overvalued or undervalued?
What is the fair value of KALY?
What is the quality score of KALY?
What is the revenue of Kali, Inc (KALY)?
What is the net profit margin of KALY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Kali, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.